How to Start a Peptide Company in 2026

Starting a peptide company in 2026 requires a clear decision about what the business actually sells and how those products are intended to be used. A company supplying genuine research materials to qualified laboratories operates under a very different framework from a telehealth clinic prescribing FDA-approved or lawfully compounded drugs. Product status, intended use, medical licensing, pharmacy relationships, advertising eligibility, payment processing, and customer-data practices all depend on that distinction.

Regulatory scrutiny is also increasing. In March 2026, the FDA issued warning letters to 30 telehealth companies over false or misleading marketing of compounded GLP-1 products. The agency has also taken action against peptide sellers whose websites suggested human use despite "Research Use Only" labeling.

That environment makes compliance part of the business model rather than a final review step. Companies evaluating peptide marketing agencies also need partners that understand how product classification and intended use affect claims, paid media, SEO, first-party data, and customer acquisition.

Key Takeaways

• The business model determines the compliance framework - Genuine research suppliers and clinical or telehealth businesses face materially different rules around product use, claims, licensing, fulfillment, and promotion
• RUO labeling alone is insufficient - FDA enforcement shows that website copy, testimonials, instructions, imagery, and other context can establish intended human drug use despite a research-only disclaimer
• Compounding rules require product-specific review - Sections 503A and 503B establish different pathways, and FDA category or advisory-committee activity should not be treated as blanket approval to compound a peptide
• Advertising and payments are conditional - Google, LegitScript, Stripe, card networks, and other providers evaluate healthcare and peptide businesses according to their actual products, licenses, claims, and operating models
• Owned growth channels need privacy controls - SEO, educational content, email, and first-party audiences can reduce platform dependence, but healthcare businesses must also consider HIPAA, state privacy laws, and data-sharing restrictions

Choose the Peptide Business Model First

The first major decision is whether the company serves a research market or provides healthcare-related products or services.

Research Use Only Businesses

A legitimate RUO company supplies products for laboratory research rather than human consumption. Its marketing, customer base, product information, fulfillment practices, and surrounding context should remain consistent with that purpose.

Simply adding "Research Use Only" or "Not for Human Consumption" to a product page does not override contradictory marketing. The FDA's 2026 Gram Peptides warning illustrates this point: the agency found intended human drug use based on website content despite RUO disclaimers.

That makes intended-use controls central to an RUO model. Product descriptions, blog content, FAQs, testimonials, social posts, dosing language, customer instructions, and advertising should all be reviewed together.

Clinical and Telehealth Businesses

A clinical peptide business operates in a healthcare environment. The company may provide medical consultations and facilitate access to FDA-approved prescription products or, where legally appropriate, compounded drugs.

This model can involve:

• Licensed healthcare providers
• State-specific professional licensing
• Medical-practice ownership requirements
• Pharmacy relationships
• Prescribing and patient-evaluation standards
• Privacy and security obligations
• Healthcare advertising certification
• Prescription-payment requirements

A company should therefore determine its clinical structure before building its website, acquisition funnel, payment stack, or multistate expansion plan.

Combining research-product sales and human clinical treatment under one loosely defined brand can create additional intended-use and compliance issues. Companies pursuing both activities need legal and regulatory review around how the operations, websites, entities, products, and marketing are separated.

Build the Regulatory Foundation

Peptide regulation cannot be reduced to a simple list of "allowed" and "prohibited" compounds.

The FDA's human compounding laws establish distinct pathways under sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act.

Understanding 503A and 503B

Under section 503A, qualifying compounded drugs generally must be prepared for an identified individual patient based on a valid prescription. Section 503A also places conditions on the bulk drug substances that can be used and on compounding products that are essentially copies of commercially available drugs.

Section 503B created outsourcing facilities. These facilities voluntarily register with the FDA, are subject to current good manufacturing practice requirements and FDA inspection, and may supply compounded drugs without first receiving a patient-specific prescription when the statutory requirements are satisfied.

The rules governing bulk substances differ between the two pathways. A substance appearing in an FDA nomination category or being discussed by an advisory committee does not automatically mean it is FDA-approved or universally lawful to compound.

BPC-157 demonstrates why that distinction matters. FDA removed BPC-157 from its earlier 503A Category 2 list after nominations were withdrawn, then convened the Pharmacy Compounding Advisory Committee in July 2026 to consider BPC-157-related substances and several other peptides for possible inclusion on the 503A Bulks List. That FDA peptide review was part of the regulatory process rather than a drug approval.

Companies should check the status of each substance against current FDA materials rather than relying on static online "peptide lists."

Account for State Medical Rules

Federal drug law is only one part of a clinical peptide company's structure.

Medical-practice ownership and control rules vary by state. California, for example, maintains a prohibition on the corporate practice of medicine and restricts non-physician control over clinical decisions. The California Medical Board specifically identifies ownership, provider hiring, patient-care decisions, coding, billing, and certain other activities as areas where improper non-physician control can create problems.

Other states apply different ownership structures, exceptions, professional-entity requirements, supervisory rules, or clinic-licensing requirements. Telehealth operators also need to evaluate professional licensing and prescribing requirements in every jurisdiction they intend to serve.

Peptide-specific rules can add another layer. In May 2026, the Alabama Board of Medical Examiners issued an official peptide notice stating that physicians may not advise, recommend, supply, prescribe, compound, administer, or dispense non-FDA-approved research-grade peptides to patients.

A multistate launch plan should therefore map medical ownership, provider licensing, pharmacy rules, prescribing requirements, telehealth standards, and product restrictions before customer acquisition begins.

Build a Qualified Supply Chain

Clinical businesses need to distinguish FDA-approved products from compounded drugs and research materials.

The FDA determined that the tirzepatide injection shortage was resolved in December 2024 and the semaglutide injection shortage was resolved in February 2025. The agency subsequently clarified limits on producing compounded products that are essentially copies of commercially available drugs.

That means the shortage-era GLP-1 environment should not be treated as the operating model for a new company in 2026.

When evaluating pharmacy or supply relationships, businesses should verify:

• Current state licenses
• Applicable FDA registration
• Whether a facility is operating under 503A or registered under 503B
• The states in which it can lawfully dispense or distribute
• Lot and product documentation
• Appropriate Certificates of Analysis
• Sterility and endotoxin testing where applicable
• Product-storage and shipping requirements
• Recall and adverse-event procedures
• Inspection and enforcement history where available

A COA is useful documentation, but it does not by itself establish that a product is lawful for human use or that a pharmacy, manufacturer, or distributor meets every applicable regulatory requirement.

Develop Claim-Safe Positioning

Peptide branding needs to match the actual product and business model.

For research businesses, the entire customer journey should reinforce legitimate research use. For clinical businesses, claims about health outcomes, treatment, weight loss, recovery, longevity, body composition, hormone function, or disease require appropriate scientific and regulatory support.

Useful trust signals can include:

• Clear company identity
• Provider credentials for clinical businesses
• Pharmacy information where appropriate
• Transparent product status
• Testing and quality documentation
• Accurate educational resources
• Clear privacy and contact information
• Straightforward refund and fulfillment policies

Claim-safe positioning does not mean removing useful information. It means avoiding promises that turn preliminary evidence, anecdotal experience, or unapproved products into established treatment claims.

Agencies with experience in regulated industry marketing can help structure content and acquisition workflows around these restrictions, although regulatory and legal review remains separate from marketing execution.

Build a Compliant Digital Acquisition Strategy

Peptide companies should not assume paid media is either completely open or completely prohibited.

Eligibility depends on the business model, product, geography, certification status, claims, landing page, and platform.

Google and LegitScript

For U.S. telemedicine providers that facilitate prescribing, Google's healthcare advertising policy requires appropriate healthcare certification. Google states that telemedicine providers must be accredited through LegitScript's Healthcare Merchant Certification Program and must also complete Google's own certification process.

LegitScript currently lists a $975 application fee and a $2,150 annual certification fee per root domain for its standard Healthcare Certification program.

Certification should not be described as automatic access to unrestricted pharmaceutical advertising. Google maintains separate rules covering prescription drug terms, unapproved substances, speculative or experimental treatment, geographic eligibility, and advertiser type.

SEO and Educational Content

Organic search gives peptide businesses another path to visibility without depending entirely on ad approval.

Useful content may address:

• Product classification
• Research terminology
• Testing and quality processes
• FDA-approved treatment categories
• How telehealth consultations work
• Pharmacy and fulfillment processes
• Storage and handling
• Frequently asked customer questions

Strong peptide SEO agencies should have a process for reviewing health-related claims rather than optimizing unsupported language simply because it has search volume.

Build Owned Audiences Carefully

Email and first-party customer relationships can reduce dependence on advertising platforms, particularly for businesses with long education or consideration journeys.

Potential owned-channel activity includes:

• Educational email subscriptions
• Consultation follow-up
• Customer onboarding
• Replenishment communication where appropriate
• Preference-based segmentation
• Lapsed-customer re-engagement
• Content-based lead generation

For a non-clinical regulated ecommerce company, first-party audience strategies illustrate how consent-based audience development can connect website traffic with email and lifecycle marketing.

Clinical businesses require additional scrutiny. HHS guidance on online tracking technologies explains that HIPAA-regulated entities can have additional obligations when tracking technologies collect or disclose protected health information. Authenticated patient pages, appointment flows, symptom information, prescription information, and other health-related interactions deserve particularly careful review.

Peptide telehealth providers should therefore evaluate tracking, analytics, CRM, email, advertising pixels, and lead-generation tools against HIPAA and applicable state privacy requirements before implementation.

Plan Payment Processing Before Launch

Payment eligibility should be confirmed before the company starts taking orders or enrolling patients.

The blanket claim that mainstream processors automatically prohibit peptides is inaccurate. Stripe's current peptide payment policy says it supports many peptides under specific conditions.

Research peptides may be eligible when preventive measures keep them from being purchased for non-research purposes. Other peptide products may require preapproval, particularly where prescription products or pharmacies are involved. Stripe also reviews telemedicine businesses individually and may request licensing and regulatory information.

That does not eliminate payment risk. It means the correct strategy is to disclose the business model accurately and confirm eligibility before processing volume.

Founders should evaluate:

• Product-specific processor eligibility
• Prescription versus non-prescription status
• Telehealth requirements
• Required licenses or certifications
• Reserve and payout terms
• Chargeback controls
• Refund procedures
• Backup operational plans

A processor application should accurately describe what the company sells. Misclassifying products to obtain payment access can create more serious problems than being declined during underwriting.

Measure Performance Around Qualified Growth

Peptide businesses need metrics that reflect the actual customer journey rather than vanity traffic.

Relevant performance indicators can include:

• Qualified organic traffic
• Consultation bookings
• Lead-to-consultation conversion
• Email audience growth
• Customer acquisition cost
• Ecommerce conversion where applicable
• Repeat purchase or refill behavior where appropriate
• Customer retention
• Revenue by acquisition source
• Assisted conversions

The applicable metrics differ between research ecommerce and clinical telehealth. A research supplier may focus heavily on product-page conversion and repeat laboratory orders, while a clinical program may care more about qualified consultations, patient acquisition, retention, and compliant lifecycle communication.

Herb Agency's full-funnel growth model similarly connects acquisition, engagement, audience development, conversion, retention, and measurement instead of evaluating each channel independently.

Building a Regulated Peptide Growth System

Peptide businesses operate in a category where marketing decisions can affect regulatory risk. Product pages, paid campaigns, SEO content, email, data collection, and payment infrastructure all need to reflect the same underlying business model.

Herb Agency's regulated growth services combine paid media where permitted, SEO, email marketing, first-party data, content, analytics, creative, direct mail, reactivation, and social strategy.

Its public performance evidence is strongest in cannabis, hemp, CBD, and adjacent regulated markets rather than peptide-specific campaigns. That distinction matters. The relevance to peptide companies comes from the operational similarities between restricted categories: platform review, claim-sensitive content, limited acquisition routes, customer education, first-party audience development, and attribution.

Current published client results demonstrate Herb Agency's work across email acquisition, programmatic advertising, content, reactivation, and direct mail for regulated brands. Those results should be treated as evidence of broader regulated-market capability rather than forecasts for a peptide company.

For a peptide business, the appropriate channel mix depends heavily on whether the company sells legitimate research products, operates a healthcare service, or participates elsewhere in the pharmaceutical supply chain. A custom growth roadmap can therefore begin with product status and acquisition eligibility before expanding into SEO, email, content, paid media, or customer retention.

Frequently Asked Questions

Is an RUO peptide company easier to start than a telehealth company?

The two models have different obligations rather than a simple difference in difficulty. A genuine RUO company does not provide treatment or sell products for human consumption, but its intended-use positioning must remain consistent across its website and marketing. A telehealth business requires healthcare licensing, clinical processes, pharmacy relationships, privacy controls, and potentially healthcare advertising certification. Founders should choose the model based on the actual intended business rather than which appears easier to launch.

Does Research Use Only labeling protect a peptide seller from FDA action?

Not by itself. FDA warning letters show that the agency can look at website content and other evidence of intended use. Human-use instructions, disease claims, dosing information, testimonials, and similar content may conflict with an RUO label. A legitimate research supplier should ensure that its overall operations and marketing consistently reflect research use.

Does a peptide telehealth company need LegitScript certification?

For U.S. telemedicine providers seeking to advertise prescription drug services through Google, Google currently requires LegitScript Healthcare Merchant Certification as well as Google's own healthcare advertiser certification. Other platforms and payment providers have separate requirements, so LegitScript should not be treated as universal permission to advertise everywhere.

Can a peptide business use Stripe?

Potentially. Stripe states that many peptide businesses can be supported, depending on the peptide's intended use, prescription status, claims, customer controls, and business model. Prescription pharmaceuticals, online pharmacies, and telehealth businesses receive additional review. Companies should obtain approval for their actual operating model rather than assuming either automatic acceptance or automatic prohibition.

What should be completed before marketing a peptide company?

The company should first establish its intended-use model, legal entity structure, product status, supplier or pharmacy relationships, required professional licensing, privacy obligations, payment eligibility, and claim-review process. Once those foundations are clear, SEO, content, email, paid media where permitted, and analytics can be built around a business model that the company can actually operate.